Future studies may be performed to evaluate whether CCL4 could be a potential therapeutic target, with either monoclonal antibody or small molecule drugs, to protect pancreatic islet and stabilize blood sugar in clinical DM. The gene discussed is CCL4; the disease is diabetes mellitus.